aaiPharma Inc., of Wilmington, N.C., appointed Michael George executive vice president and chief administrative officer, and John Harrington executive vice president of human resources.

Acologix Inc., of Emeryville, Calif., appointed Aki Watanabe to its board.

Adaptis Inc., of Seattle, appointed Catherine Gronlund vice president of research and development.

Advanced Magnetics Inc., of Cambridge, Mass., appointed Brain Pereira to its board.

Affymax Inc., of Palo Alto, Calif., appointed Anne-Marie Duliege vice president of clinical, medical and regulatory affairs.

Alimera Sciences Inc., of Atlanta, appointed Mark Brooks, Brian Halak, Steve Martin, Terry McGuire, Calvin Roberts and Phil Tracy to its board.

Allegent Technology Group, of Woodbury, N.Y., appointed Thomas Donohue to its board.

AlphaVax, of Research Triangle Park, N.C., hired Andrew Graham as its vice president of development.

Altus Pharmaceuticals Inc., of Cambridge, Mass., appointed Don Burstyn vice president, regulatory affairs.

Antares Pharma Inc., of Exton, Pa., appointed Jack Stover president and chief operating officer.

Antigenics Inc., of New York, appointed Roman Chicz senior vice president of research and preclinical development.

Archemix Corp., of Cambridge, Mass., appointed Augustine Yee vice president, business development.

ArQule Inc., of Woburn, Mass., appointed Daniel Von Hoff to its scientific advisory board.

AusAm Biotechnologies Inc., of New York, appointed Mark Straley chief operating officer.

Baxter International Inc., of Deerfield, Ill., named Joy Amundson corporate vice president and president of its bioscience business.

Biogen Idec Inc., of Cambridge, Mass., appointed Michael Gilman executive vice president of research, and Mark Wiggins executive vice president of business development.